Composition and method for producing low cholesterol eggs

Food or edible material: processes – compositions – and products – Products per se – or processes of preparing or treating... – Poultry egg is basic ingredient

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C426S002000

Reexamination Certificate

active

06177121

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to an animal food composition effective in reducing the level of cholesterol in an egg and a method of producing low cholesterol eggs. More specifically, the invention relates to an animal food composition including an animal food and a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. The invention further relates to a method of producing low cholesterol eggs by administering an HMG-CoA reductase inhibitor to an egg-laying animal. The eggs so produced are also described.
BACKGROUND OF THE INVENTION
Coronary heart disease is one of the leading causes of death in the United States. The relationship between elevated plasma cholesterol levels, especially plasma low density lipoprotein (LDL) cholesterol, and an increased risk of contracting coronary heart disease has been well established. In light of this relationship, a dietary cholesterol intake of less than 300 mg/day has been recommended for all Americans (National Institutes of Health Consensus Development Panel, 1985). Foodstuffs containing lowered levels of cholesterol are therefore desired.
Each chicken egg contains about 215 mg cholesterol. Efforts at reducing the level of cholesterol in intact chicken eggs have included genetic selection, use of low fat and high fiber diets, administration of pharmacological agents and various egg selection methods. Many of these methods are tedious and others have not led to large decreases in egg cholesterol. An animal food composition effective in reducing the amount of cholesterol in an egg and a method of producing low cholesterol eggs are therefore needed. The present invention addresses these needs.
SUMMARY OF THE INVENTION
The present invention relates to an animal food composition including an animal food and an HMG-CoA reductase inhibitor. The animal food composition is preferably an oviparous vertebrate food composition. The animal food composition is effective in reducing the amount of cholesterol in an egg. The HMG-CoA reductase inhibitor is preferably a compound having the following formula:
wherein
R
1
is C
3-10
cycloalkyl; C
1-10
alkyl provided that the C
1-10
alkyl is not 1-methylpropyl if R
2
and R
3
are both methyl groups; C
1-10
CF
3
-substituted alkyl; phenyl; halophenyl; phenyl-C
1-3
alkyl; substituted phenyl-C
1-3
alkyl in which the substituent is halo, C
1-3
alkyl or C
1-3
alkoxy;
R
2
is H, C
1-10
alkyl, or hydroxyl;
R
3
is H, C
1-10
alkyl;
the dotted lines at X, Y and Z represent possible double bonds, said double bonds when present being either X and Z in combination or X, Y or Z alone;
or the corresponding dihydroxy acid, a pharmaceutically acceptable salt of said acid, a C
1-4
alkyl ester of said acid, a phenyldimethylamino-substituted-C
1-4
alkyl ester of said acid or an acetylamino-substituted-C
1-4
alkyl ester of said acid.
In yet another embodiment of the present invention, the HMG-CoA reductase inhibitor is a compound of the following formula:
wherein
X is —CH
2
—, —CH
2
CH
2
—, —CH
2
CH
2
CH
2
— or —CH
2
CH(CH
3
)—;
R
1
is 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; 2-, 3- or 4-pyridinyl-N-oxide; 2-, 3- or 4-(N—C
1-4
alkyl) pyridinium halide; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C
1-4
alkyl, C
1-4
alkoxy, C
2-8
alkanoyloxy; C
1-8
alkyl;
R
2
and R
3
are independently hydrogen; cyano; trifluoromethyl; phenyl; C
1-4
alkyl; C
2-8
carboalkoxy; CH
2
OR
7
where R
7
is hydrogen, C
1-6
alkanoyl, —CONHR
8
where R
8
is a C
1-6
alkyl, phenyl or phenyl substituted with halogen or C
1-4
alkyl; halogen provided that if R
1
is 1-methylethyl, R
4
is 4-fluorophenyl and either of R
2
or R
3
is bromine, the other of R
2
or R
3
is not bromine; or
either of R
2
or R
3
is —CONR
5
R
6
where R
5
and R
6
are independently hydrogen; C
1-6
alkyl; 2-, 3- or 4-pyridinyl; phenyl; phenyl substituted with halogen, cyano, trifluoromethyl or C
3-8
-carboalkoxy; and the other of R
2
or R
3
is hydrogen; C
1-6
alkyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C
1-4
alkyl, C
1-4
alkoxy, or C
2-8
alkanoyloxy; and
R
4
is C
1-6
alkyl, cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; trifluoromethyl; phenyl; or phenyl substituted with halogen;
or the corresponding dihydroxy acid.
In yet another embodiment of the invention, a method of lowering the amount of cholesterol in an egg is provided that includes administering to an egg-laying animal an effective amount of the above-described compounds. The method is preferably carried out with chickens but may be carried out with any oviparous vertebrate, including turkey, geese, quail, rattites (including ostriches, emus and rheas) turtles and fish.
In a further embodiment of the present invention, an egg produced by the above-method is also described.


REFERENCES:
patent: 3983140 (1976-09-01), Endo et al.
patent: 4049495 (1977-09-01), Endo et al.
patent: 4137322 (1979-01-01), Endo et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4432996 (1984-02-01), Gullo et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4603142 (1986-07-01), Burger et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 5273995 (1993-12-01), Roth
Krause, R. Brian and Newton, Roger S., “Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rate correlates with efficacy in LDL animal models,”Atherosclerosis117 (1995) 237-244.
Conde, Karin; et al., “Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig”,Journal of Lipid Research, vol. 37, 1996.
Griffin, H.D., “Manipulation of egg yolk cholesterol: a physiologist's view,”World's Poultry Science Journal, vol. 48, Jul. 1992.
Luhman, Cindie, M.; Miller, Bryan G. and Beitz, Donald C., “Research Note: The Effect of Feeding Lovastatin and Colestipol on Production and Cholesterol Content of Eggs”,1990 Poultry Science 69:852-855.
Elkin, Robert G. and Rogler, John C., “Reduction of the Cholesterol Content of Eggs by theOral Administration of Lovastatin to Laying Hens”,Journal of Agricultural and Food Chemistry, 1990, 38.
Elkin, Robert G. et al., “Alterationof Egg Yolk Cholesterol Content and Plasma Lipoprotein Profiles following Administration of a Totally Synthetic HMG-CoA Reductase Inhibitor to Laying Hens,”Journal of Agricultural and Food Chemistry, 1993, 41.
Gotton, Jr., Antonio M.; Smith, Louis C. and Allen, Barbara,Athero-Sclerosis V, Springer-Verlag, New York, 1980.
Huggett, Christine D., Buttery, Peter J. and Salter, Andrew M., “Plasma VLDL cholesterol and egg cholesterol are resistant to change inthe laying hen”,Biochemical Society Transactions(1993) vol. 21, pp. 1475.
Hargis, P. Stewart, “Modifying egg yold cholesterol in the domestic fowl—a review”, World's Poultry Science Journal vol. 44 (1988).
“Cerivastatin Posters Presented at Scientific Meetings 1997”, Bayer, 1997, pp. 1-4.
“Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor”, Nawrocki et al., Arterioscler. Thromb. Vasc. Biol., 1995, vol. 15, pp. 678-682.
“Efficacy and Safety of New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients with Hypertriglyceridemia”, Bakker-Arkema et al., JAMA, Jan. 10, 1996, vol. 275, No. 2, pp. 128-133.
“Inhibitors of Cholesterol Biosynthesis”, Roth et al., Journal of Medicinal Chemistry, 1991, vol. 34, No. 1, pp. 357-366.
“The Discovery and Development of HMG-CoA Reductase Inhibitors”, Endo, Journal of Lipid Research, 1992, vol. 33, pp. 1569-1582.
Database Abstract. 102:4947 HCA Low-cholesterol egg production. JP 59029209, Jul. 1984.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Composition and method for producing low cholesterol eggs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition and method for producing low cholesterol eggs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for producing low cholesterol eggs will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2505656

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.